Health knowledge made personal
Join this community!
› Share page:
Search posts:

UOK 268 Cell Line for Hereditary Leiomyomatosis and Renal Cell Carcinoma

Posted Mar 14 2011 8:00pm

Description of Invention:
Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is an extremely aggressive cancer syndrome with no effective treatment regimen and currently no cure. The progress of identifying HLRCC treatments and cures has likely been hindered due to the lack of an HLRCC model for studying the cancer syndrome and for screening therapeutic drug candidates.

This technology describes the UOK 268 cell line, a spontaneously immortalized renal tumor cell line that may be of great interest to industry for studying HLRCC, drug screening, and searching for tumor markers related to diagnosis, prognosis, and drug resistance. This cell line is only the second spontaneously immortalized cancer cell line of its kind in the world and is unique in that it is a primary tumor cell model (the other cell line, UOK 262, is from a metastasis cell model). The UOK 268 cell line is an established, clonal, immortalized renal cancer cell line derived from the long-term culture of aggressive tumor tissues of HLRCC in a specially designed culture medium under strict culture conditions. The UOK 268 exhibits an array of HLRCC kidney cancer characteristics that can promote protein and fatty acid biosynthesis and modulate HIF activities in a manner conducive to cancer cell proliferation.

  • This is only one of two immortalized HLRCC cell lines, and is unique in that it is from a primary tumor cell model.
  • Developing a diagnostic to search for tumor targets and screen for HLRCC and related cancers drug candidates will have significant benefits, including early detection and treatment.

  • In vitro and in vivo cell model for understanding the biology of HLRCC and related cancers, including growth, motility, invasion, and metabolite production.
  • High throughput screening to test for drug candidates that could be used to treat particular cancers, such as HLRCC.
  • Diagnostic tool for the diagnosis, prognosis, and drug resistance of tumor markers.

  • Cell line is derived from a HLRCC patient: This cell line is anticipated to retain many features of primary HLRCC samples and novel HLRCC antigens identified from this cell line are likely to correlate with antigens expressed on human HLRCC tumors. Studies performed using this cell lines may have a direct correlation to the initiation, progression, treatment, and prevention of HLRCC in humans.
  • Molecular and genetic features are well characterized: The inventors have elucidated many physical characteristics of the cell line and their data reveals previously unrecognized coordination between mammalian glucose and iron metabolisms through AMPK signaling, and a novel mechanism for modulating HIF activities in renal cancers.

W Marston Linehan (NCI)
Youfeng Yang (NCI)

Patent Status:
HHS, Reference No. E-254-2010/0

Research Tool — Patent protection is not being pursued for this technology.

Relevant Publication:
  1. Youfeng Yang et al. Distinct Mito-transcriptome Profiling in Fumarate Hydratase-deficient Novel Primary Tumor Cell Line UOK268 Leads to Better Understanding of Early Human HLRCC-associated Cancer with Multiple Dysregulated Molecular Events and Metabolic Shunts. Under submission.
  2. Wing-Hang Tong et al. Hypoactivation of AMPK pathway and remodeling of iron metabolism in hereditary leiomyomatosis and renal cell carcinoma tumorigenesis. Under resubmission.

Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The Center for Cancer Research, Urologic Oncology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize UOK268 as human HLRCC primary cell line model to comparing previously established UOK262, which was from metastasis lympho node. UOK 268 is a unique cell model for studying the underlying molecular derangements associated with impaired oxidative phosphorylation in cancer and for evaluating novel therapeutic approaches for this HLRCC-associated kidney cancer. Please contact John Hewes, Ph.D. at 301-435-3121 or for more information.

Devices/Instrumentation - Research Tools and Materials
Cancer - Research Materials

For Licensing Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-451-7337
Fax: 301-402-0220

Ref No: 2240

Updated: 03/2011

Post a comment
Write a comment:

Related Searches